Access to new cholesterol-lowering drugs is so tightly controlled and patients’ out-of-pocket costs are so high that fewer than a third of those doctors prescribe the drugs get them, a new study found.
Access to new cholesterol-lowering drugs is so tightly controlled and patients’ out-of-pocket costs are so high that fewer than a third of those doctors prescribe the drugs get them, a new study found. Dreamstime TNS
Access to new cholesterol-lowering drugs is so tightly controlled and patients’ out-of-pocket costs are so high that fewer than a third of those doctors prescribe the drugs get them, a new study found. Dreamstime TNS

Out-of-pocket costs often keep pricey new cholesterol drugs out of reach, study finds

October 06, 2017 08:40 PM

More Videos